Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists
Madeleine M. Fletcher, Peter Keov, Tin T. Truong, et al.
Journal of Pharmacology and Experimental Therapeutics (2021) Vol. 377, Iss. 3, pp. 417-440
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Andrew F. Russo, Debbie L. Hay
Physiological Reviews (2022) Vol. 103, Iss. 2, pp. 1565-1644
Open Access | Times Cited: 157
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 30
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angeliki M. Angelidi, Matthew J. Belanger, Alexander Kokkinos, et al.
Endocrine Reviews (2021) Vol. 43, Iss. 3, pp. 507-557
Open Access | Times Cited: 81
Development of Cagrilintide, a Long-Acting Amylin Analogue
Thomas Kruse, Jakob Lerche Hansen, Kirsten Dahl, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 11183-11194
Open Access | Times Cited: 67
A structural basis for amylin receptor phenotype
Jianjun Cao, Matthew J. Belousoff, Yi-Lynn Liang, et al.
Science (2022) Vol. 375, Iss. 6587
Closed Access | Times Cited: 47
Creating the amylin story
Thomas A. Lutz
Appetite (2022) Vol. 172, pp. 105965-105965
Open Access | Times Cited: 33
Mediators of Amylin Action in Metabolic Control
Christina N. Boyle, Yi Zheng, Thomas A. Lutz
Journal of Clinical Medicine (2022) Vol. 11, Iss. 8, pp. 2207-2207
Open Access | Times Cited: 33
Amylin as a Future Obesity Treatment
Babak Dehestani, Nicholas RS Stratford, Carel W. le Roux
Journal of Obesity & Metabolic Syndrome (2021) Vol. 30, Iss. 4, pp. 320-325
Open Access | Times Cited: 35
Long-acting amylin analogues for the management of obesity
David S. Mathiesen, Jonatan I. Bagger, Filip K. Knop
Current Opinion in Endocrinology Diabetes and Obesity (2022) Vol. 29, Iss. 2, pp. 183-190
Closed Access | Times Cited: 27
Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins
Ilana B. Kotliar, Emily Lorenzen, Jochen M. Schwenk, et al.
Pharmacological Reviews (2022) Vol. 75, Iss. 1, pp. 1-34
Open Access | Times Cited: 27
Development of a Novel Assay for Direct Assessment of Selective Amylin Receptor Activation Reveals Novel Differences in Behavior of Selective and Nonselective Peptide Agonists
Peter Keov, George Christopoulos, Caroline A. Hick, et al.
Molecular Pharmacology (2024) Vol. 105, Iss. 5, pp. 359-373
Open Access | Times Cited: 5
Variable CGRP family peptide signaling durations and the structural determinants thereof
Katie M. Babin, Sandra E. Gostynska, Jordan A Karim, et al.
Biochemical Pharmacology (2024) Vol. 224, pp. 116235-116235
Closed Access | Times Cited: 5
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
Antonella M. D’Ascanio, Jamie Mullally, William H. Frishman
Cardiology in Review (2023) Vol. 32, Iss. 1, pp. 83-90
Closed Access | Times Cited: 12
Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatment
Jens Bjelke Kristensen, Lisbeth Elster, Morten Lundh, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors
Jianjun Cao, Matthew J. Belousoff, Rachel M. Johnson, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics
Zoe Tasma, Michael L. Garelja, Aqfan Jamaluddin, et al.
Pharmacology & Therapeutics (2025), pp. 108846-108846
Open Access
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Kim Henriksen, Manu V. Chakravarthy, Cecilie Liv Bager, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models
Anna Thorsø Larsen, Khaled Elhady Mohamed, Nina Sonne, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113842-113842
Open Access | Times Cited: 16
Drugs for Treating Obesity
Donna H. Ryan
Handbook of experimental pharmacology (2021), pp. 387-414
Closed Access | Times Cited: 23
Lipidated Calcitonin Gene-Related Peptide (CGRP) Peptide Antagonists Retain CGRP Receptor Activity and Attenuate CGRP Action In Vivo
Aqfan Jamaluddin, Chia-Lin Chuang, Elyse T. Williams, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 14
The processing intermediate of human amylin, pro-amylin(1–48), has in vivo and in vitro bioactivity
Giulia Mazzini, Christelle Le Foll, Christina N. Boyle, et al.
Biophysical Chemistry (2024) Vol. 308, pp. 107201-107201
Open Access | Times Cited: 2
THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin – physiology and pharmacology
David S. Mathiesen, Asger Lund, Jens J. Holst, et al.
European Journal of Endocrinology (2022) Vol. 186, Iss. 6, pp. R93-R111
Open Access | Times Cited: 11
Structural insight into selectivity of amylin and calcitonin receptor agonists
Jianjun Cao, Matthew J. Belousoff, Elliot Gerrard, et al.
Nature Chemical Biology (2023) Vol. 20, Iss. 2, pp. 162-169
Open Access | Times Cited: 6
Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research
Tayla A. Rees, Alejandro Labastida‐Ramírez, Eloísa Rubio‐Beltrán
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 10, pp. 651-663
Open Access | Times Cited: 6
Cagrilintide plus semaglutide for obesity management
Sara Becerril, Gema Frühbeck
The Lancet (2021) Vol. 397, Iss. 10286, pp. 1687-1689
Closed Access | Times Cited: 14
Page 1 - Next Page

Scroll to top